ArticleJournal of clinical laboratory analysis2022
Circular RNA mitochondrial translation optimization 1 correlates with less lymph node metastasis, longer disease-free survival, and higher chemotherapy sensitivity in gastric cancer.
Article in Journal of clinical laboratory analysis, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 9 citations in OpenAlex.
- Circular RNAs: emerging regulators of oxaliplatin response and resistance in cancer therapy.Medical oncology (Northwood, London, England) · 2025Review
- ncRNAs as Key Regulators in Gastric Cancer: From Molecular Subtyping to Therapeutic Targets.Annals of surgical oncology · 2025Review
- Mechanisms and therapeutic strategies to reveal and overcome T-cell dysfunction in gastric cancer: translation from basic research to clinical application.Frontiers in immunology · 2025Review
- Emerging roles of circular RNAs in tumorigenesis, progression, and treatment of gastric cancer.Journal of translational medicine · 2024Review
- Interplay of circular RNAs in gastric cancer - a systematic review.Frontiers in systems biology · 2024Review
- CircSCUBE3 Reduces the Anti-gastric Cancer Activity of Anti-PD-L1.Molecular biotechnology · 2024Article
- Circular RNA mitochondrial translation optimization 1 correlates with less lymph node metastasis, longer disease-free survival, and higher chemotherapy sensitivity in gastric cancer.Journal of clinical laboratory analysis · 2022Article
- Circular RNAs as diagnostic biomarkers for gastric cancer: A comprehensive update from emerging functions to clinical significances.Frontiers in genetics · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveCircular-mitochondrial translation optimization 1 (circ-MTO1) inhibits the progression of gastric cancer by regulating the growth, apoptosis, and invasion of tumor cells. However, its clinical potential as a biomarker for gastric cancer remains to be further evaluated. This study aimed to assess circ-MTO1 expression and its correlation with clinical features and prognosis in gastric cancer patients, as well as the effect of circ-MTO1 on the sensitivity to chemotherapy in gastric cancer cells.
methodsCirc-MTO1 in tumor and adjacent tissues of 97 gastric cancer patients undergoing resection was examined by reverse transcription-quantitative polymerase chain reaction. HGC-27 and NCI-N87 cells transfected by circ-MOT1 overexpression plasmid (OE-circ-MOT1) and negative control (OE-NC) were treated with 0-6.4 μM oxaliplatin. Relative cell viability was detected using Cell Counting Kit-8.
resultsCirc-MTO1 was insufficiently expressed in gastric tumor tissue (median (interquartile range): 0.403 (0.288-0.518)) compared with adjacent tissue (median (interquartile range): 1.000 (0.715-1.524)) (p < 0.001). Besides, tumor circ-MTO1 was correlated with less lymph node metastasis (p = 0.014) and low TNM stage (p = 0.039), while was not correlated with demographic features or other clinical characteristics (all p > 0.05). Furthermore, tumor circ-MTO1 high expression was independently correlated with prolonged disease-free survival (DFS) (p = 0.013, adjusted hazard ratio (95% confidential interval): 0.314 (0.126-0.782)), but was not correlated with overall survival (p > 0.05). Lastly, in gastric cancer cells, OE-circ-MTO1 apparently decreased relative cell viabilities at oxaliplatin concentrations of 0.4, 0.8, 1.6, and 3.2 μM (all p < 0.05).
conclusionCirc-MTO1 correlates with less lymph node metastasis, prolonged DFS, and improved chemotherapy sensitivity in gastric cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.